MAPK

Items 51-100 of 239

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. Raf-1 Inhibitor

    GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor
  2. MEK1 inhibitor

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases.
  3. MEK1/2 inhibitor

    MEK162 (ARRY-438162) is a potent, selective, ATP uncompetitive inhibitor of MEK1/2.
  4. VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitor

    Regorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
  5. p38 MAPK inhibitor

    SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
  6. p38 MAPK inhibitor

    SD-06 is a p38 MAP kinase inhibitor; inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po).
  7. p38 MAPK inhibitor

    TAK 715 an inhibitor of p38 MAPK (IC50 = 7.1 nM for p38 MAPKα), Wnt/beta-catenin signaling, and Inhibits 22 kinases by more than 80%, including CK 1δ/ε.
  8. BMK1/ERK5 inhibitor

    XMD8-92 is a potent and selective BMK1/ERK5 inhibitor .
  9. nAChR agonist

    Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.
  10. ERK1/ERK2 inhibitor

    VRT752271 is a pyrrole inhibitors of ERK protein kinase.
  11. JNK Inhibitor IX

    TCS JNK 5a is a highly selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38?? respectively).
  12. Raf kinase inhibitor

    Sorafenib N-Oxide is a metabolite of Sorafenib, a potent Raf kinase inhibitor.
  13. Asiaticoside (Madecassol) is the active chemical component of the plant Centella asiatica. Asiaticoside is used to study potential treatments for wounds and burns.
  14. trans-Zeatin is a member of the plant hormone family known as ??cytokinins??, which regulate cell division, development, and nutrient processing.
  15. MAP4K4 inhibitor

    GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.
  16. p38 MAPK inhibitor

    ML-3043 is a p38 MAPK inhibitor (IC50 = 0.38 μM). Inhibits the release of IL-1β and TNF-α in a peripheral blood mononuclear cell (PBMC) assay (IC50 values are 0.039 and 0.16 μM respectively).
  17. MLKL inhibitor

    TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC50 value of 2 nM for HT-29 cells.
  18. ERK2 inhibitor

    TCS ERK 11e (VX-11e) is a potent and selective extracellular signal-related kinase 2 (ERK2) inhibitor (Ki values are <2, 395, 540 and 852 nM for ERK2, GSK-3, Aurora Kinase A and Cdk2 respectively). Potently blocks proliferation of HT29 cells (IC50 = 48 nM).
  19. p38 MAPK inhibitor

    Losmapimod, also know as GW856553 or GW856553X, is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases.
  20. RAF inhibitor

    PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively.
  21. JNK Inhibitor

    JNK-IN-8 is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK4 with IC50 of 4.7 nM, 18.7 nM and 1 nM, respectively
  22. p38 MAPK inhibitor

    Talmapimod (SCIO-469) is a selective, ATP-competitive p38 inhibitor (IC50 = 9 nM for p38α in vitro).
  23. ERK Inhibitor

    SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively.
  24. MEK1/2 inhibitor

    Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
  25. food flavouring

    2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways.
  26. RAS/RAF/MAPK inhibitor

    Diazepinomicin, also known as TLN-4601, is a small-molecule inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity.
  27. MEK1 inhibitor

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
  28. Ras/Raf/MEK inhibitor

    Balamapimod, also known as MKI-822, is a Ras/Raf/MEK inhibitor.
  29. MEK inhibitor

    EBI-1051 is a highly potent and orally efficacious MEK inhibitor with an IC50 of 3.9 nM.
  30. pan RAF inhibitor

    Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
  31. Selective B-RAF Inhibitor

    LGX818 is an orally available Raf kinase inhibitor with potential antineoplastic activity.
  32. MEK1 inhibitor

    RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity.
  33. pan-RAF inhibitor

    TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A375) IC50, 12 nM; pMEK (HMVII), 49 nM; V/B ratio.
  34. ERK1/2 inhibitor

    GDC-0994 is a potent and selective Erk1/2 inhibitor. GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways.
  35. Raf inhibitor

    L-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
  36. p38 MAPK inhibitor

    Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor.
  37. p38 MAPK inhibitor

    RWJ-67657 is a potent p38 MAPK inhibitor.
  38. p38 MAPK inhibitor

    Dilmapimod is p38 MAPK inhibitor.
  39. p38 MAPK inhibitor

    BMS-582949 Is a Dual Action p38 Kinase Inhibitor Well Suited To Avoid Resistance Mechanisms That Increase p38 Activation in Cells.
  40. JNK inhibitor

    CC-930 is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ?? 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ?? 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively
  41. JNK inhibitor

    CEP-1347 is an inhibitor of c-jun N-terminal kinase (JNK) signaling. It rescues motor neurons undergoing apoptosis (EC50 = 20 nM).
  42. MAPKAP-K2 (MK-2) inhibitor

    MK-2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.
  43. p38 MAPK inhibitor

    TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM.
  44. p38 MAPK inhibitor

    SB-242235 is a potent and selective p38 MAP kinase inhibitor that may be an effective therapy for cytokine-mediated diseases such as autoimmune or inflammatory diseases.
  45. JNK inhibitor

    BI-78D3 is a competitive JNK (c-Jun N-terminal kinases) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K. BI 78D3 inhibits JIP1(JNK interacting protein 1)-JNK binding (IC50 = 500 nM).
  46. Hypothemycin is a resorcylic acid lactone polyketide. It was found to inhibit the proliferation of mouse and human T cells stimulated with anti-CD3 mAb + PMA and of human PBMC stimulated with anti-CD3 mAb alone.
  47. ERK5 inhibitor

    BAY885 is a novel ERK5 inhibitor.
  48. Raf inhibitor

    CEP-32496 is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity.
  49. MNK2 inhibitor

    CGP 57380 is an inhibitor of MAP-kinase interacting kinase-1 (Mnk1, MKNK1) (IC50 = 2.2 uM).
  50. CK2/ERK8 inhibitor

    MCB has been shown to inhibit both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8/MAPK15) (IC50 = 0.50 uM for both CK2 and ERK8).

Items 51-100 of 239

per page
Set Descending Direction